AstraZeneca Pharma India Limited
ASTRAZEN · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹3,401.2.
Piotroski F-score 0/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%22.8%
- ✓Low debt (D/E < 0.5)0.13x
- ✕Positive free cash flow
- ✓Revenue growth > 10%20%
- ✕Earnings growing-23%
- ✕Net margin ≥ 10%8.2%
- ✓Current ratio > 1.51.77
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 12.75
- ✕Piotroski ≥ 70/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (22.8%).
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 12.75.
Weaknesses
- •Price below its 200-day moving average (downtrend).
- •Weak Piotroski score (0/9).
Opportunities
- •Revenue growing (20% YoY).
Threats
- •Earnings contracting year on year.
- •Rich valuation versus sector peers.
- •Trades ~50% above our estimated fair value.
About AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also o
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.